Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
What volumes would you cover in a young patient with otherwise low risk breast cancer in whom the sentinel node failed to map and ALND was not performed?
How would you manage a patient with micrometastatic node positive tumor post mastectomy (no neoadjuvant chemotherapy)?
What is the earliest you would start postmastectomy radiation after adjuvant chemotherapy for a patient with breast cancer?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
Would you offer PMRT when the only indication is a focally positive margin?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
Does a post-surgical hematoma in the breast affect your recommendations for partial breast RT?
Would you offer partial breast radiation to a young breast cancer patient with BRCA 1 if all other criteria are met?
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
